Canine hemangiosarcoma (HSA) is a neoplasm of vascular endothelial origin that has an aggressive biological behaviour, with less than 10% of dogs alive at 12-months postdiagnosis. Treatment of choice consists of surgery followed by adjuvant doxorubicin-based chemotherapy. We prospectively compared adjuvant doxorubicin and dacarbazine (ADTIC) to a traditional doxorubicin and cyclophosphamide (AC) treatment, aiming at determining safety and assessing whether this regimen prolongs survival and time to metastasis (TTM). Twenty-seven dogs were enrolled; following staging work-up, 18 were treated with AC and 9 with ADTIC. Median TTM and survival time were longer for dogs treated with ADTIC compared with those receiving AC (>550 versus 112 days, P = 0.021 and >550 versus 142 days, P = 0.011, respectively). Both protocols were well tolerated, without need for dose reduction or increased interval between treatments. A protocol consisting of combined doxorubicin and dacarbazine is safe in dogs with HSA and prolongs TTM and survival time.
Introduction
Hemangiosarcoma (HSA) is a common tumour in dogs, occurring in three different forms: dermal, subcutaneous/muscular and visceral, the latter mainly involving spleen, right atrium or auricle, and liver. 1 -3 With the exception of the dermal form, which may behave in a less aggressive fashion, subcutaneous/intramuscular and visceral HSA is a highly malignant cancer, spreading rapidly to lungs, liver, peritoneum and central nervous every 3 weeks, one study attempting to increase dose intensity by more frequent administrations showed such strategy to be well tolerated, although without improved survival time. 13 A metronomic strategy has also been proposed as an alternative treatment, yielding comparable results with conventional dose-intense chemotherapy. 14 More recently, a combined chemotherapy protocol consisting of doxorubicin, dacarbazine and vincristine (DAV) was evaluated in metastatic canine HSA. 15 Results suggested that the DAV combination offers clinical response and might prolong survival in dogs with advanced clinical stage HSA. These patients typically have a grave prognosis, and treatment options different from hospice or euthanasia are usually discouraged. Thus, the results obtained in the aforementioned study raised interest towards the use of dacarbazine for the treatment of canine HSA. However, significant haematological and/or gastrointestinal toxicities were observed with DAV, leading to discontinuation of treatment in almost 20% of the patients. 15 Dacarbazine is a non-classical alkylating, phase non-specific agent, which methylates the deoxyribonucleic acid (DNA) at the O 6 methyl group of guanine. 16 Dacarbazine has previously been used in dogs for the treatment of relapsed or resistant lymphomas, high-grade sarcomas and malignant melanomas, either as single agent or combined with lomustine or doxorubicin. 17 -22 Results of in vitro and in vivo studies suggest that dacarbazine acts synergistically with anthracyclines and has a moderate effect on the treatment of high-grade sarcomas in humans, leading to the need of further investigations of this compound in the treatment of canine HSA. 23 -25 As single agent, a dose up to 1000 mg m −2 intravenously (IV) over 6-8 h and 1500 mg m −2 as a single bolus may be administered to dogs and humans, respectively, every 3-4 weeks 16, 19, 26, 27 ; however, these regimens have largely been replaced in human practice by a daily dose of 250 mg m −2 administered over 5 consecutive days, leading to reduced gastrointestinal toxicity besides similar antitumour activity. 16, 28 In this study, we prospectively compared adjuvant chemotherapy with doxorubicin and daily dacarbazine boluses (ADTIC) to a traditional doxorubicin and cyclophosphamide (AC) treatment, aiming at determining safety and assessing whether this regimen prolongs survival time and time to metastasis (TTM) in dogs with biologically aggressive HSA that underwent surgical intervention.
Materials and methods

Patient eligibility
Client-owned dogs with a surgically removed, histologically confirmed HSA, arising from any abdominal organ or subcutis, were prospectively recruited. Presurgical investigations included physical examination, haematology, serum biochemistry, abdominal ultrasound and at least two lateral views thoracic radiographs. Dogs were considered to be at high risk of developing doxorubicin-related cardiotoxicity if systolic fractional shortening determined by using echocardiography was <25%. Dogs with such cardiac function were not enrolled in this study. Dogs with life-limiting diseases different than HSA and those with dermal HSA were also excluded. Dogs were staged according to the World Health Organization (WHO) staging system for domestic animals. 29 . Dogs referred to the institution of one author (D. S.) were included in group 1, whereas dogs referred to the institutions of two different authors (L. M. and R. F.) were included in group 2.
Treatment protocol
The objective was to initiate chemotherapy within 7-10 days after surgical intervention. Dogs included in group 1 were treated with adjuvant doxorubicin (Doxorubicina, Ebewe Italia s.r.l., Roma, Italy) and cyclophosphamide [Endoxan ® , Baxter s.r.l., Lurago d'Erba, Como, Italy (AC)], whereas dogs included in group 2 received adjuvant doxorubicin and dacarbazine [Deticene ® , Aventis Pharma S.p.A, Milano, Italy (ADTIC)].
ADTIC was more expensive compared with AC, and as the study was not supported by a grant, groups could not be randomized. Because ADTIC was completely investigational at the time this study was carried out compared with the traditional AC protocol, all owners electing ADTIC were asked to sign a written informed consent prior to enrolment. In either treatment groups, doxorubicin was administered IV at the dose of 30 mg m −2 every 3 weeks for four cycles. Doxorubicin was administered as a slow IV bolus within 20 min. In group 1, cyclophosphamide was administered orally at 75 mg m −2 for 4 consecutive days, starting on the day of every doxorubicin administration. In group 2, dacarbazine was administered IV at the dose of 200 mg m −2 (without exceeding 250 mg total daily) once daily for 5 days, starting on the day of every doxorubicin administration. Briefly, dacarbazine was reconstituted with water for injection to obtain a concentration of 10 mg mL −1 . Reconstituted drug was then given by intravenous infusion over 1 min via the indwelling catheter previously placed to administer doxorubicin. The catheter was then removed, and a new catheter was repeatedly placed for the following four administrations. Fractional and summation dose intensities (SDIs) for the two protocols are listed in Table 1 .
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In either group, standard antiemetic therapy consisted in maropitant (Cerenia ® , Pfizer, Latina, Italy) administered orally at the dose of 2 mg kg −1 q24h for 3 consecutive days starting on the first day of chemotherapy. Clavulanate-potentiated amoxicillin (Synulox ® , Pfizer, Latina, Italy) was prophylactically administered orally at 12.5-20 mg kg −1 q12h until the time of the expected neutropenic nadir, and as indicated thereafter. Antibiotic dosage depended on clinician's preference.
A repeated clinical staging work-up consisting of thoracic radiographs and abdominal ultrasound was performed after two cycles of chemotherapy. If no local recurrence and/or metastatic disease were observed, the same chemotherapy protocol was continued for two additional cycles. In case of disease progression, a rescue protocol was offered. Follow-up re-staging consisted of thoracic radiographs and abdominal ultrasound performed 1 month after the end of the protocol and every 3 months afterwards to define response to treatment.
Assessment of toxicity
Toxicity resulting from chemotherapy was assessed in group 1 based on the dog's history, physical examination and complete blood count (CBC) performed 7-10 days after doxorubicin and before the beginning of each cycle, as stated by the Veterinary Co-operative Oncology Group. 31 In group 2, CBC was checked on days 1, 4, 5 and 10 of each chemotherapy cycle. Day 1 was considered as the day of doxorubicin administration.
Statistical analysis
Follow-up and survival times were calculated from the date of diagnosis to the date of last visit or death based on the rechecks performed at one of the authors' institutions. For both groups, survival time and TTM (beyond regional lymph nodes) were explored using the Kaplan-Meier product limit method followed by log-rank test. In either group, timing was considered from surgical excision. In the survival analysis, dogs were censored if they were alive at the time of data accrual closure or died of no tumour-related causes, whereas for TTM dogs were censored if, by the last examination, distant metastases had not developed.
To verify whether characteristics of the two treatment groups differed at admission, the Mann-Whitney test was used to compare age and body weight, and the Fisher's exact test was used to compare breed (pure-versus cross-breed), sex (male versus female), primary location of the tumour (spleen versus other sites), clinical stage (II versus III) and surgical margins (complete versus incomplete). Surgical margins were deemed not assessable if the dog was presenting with visceral rupture. The Fisher's exact test was also used to compare the frequency of bone marrow toxicity (present versus absent) that occurred during treatment cycles. P < 0.05 was considered significant.
Results
Between 2008 and 2014, 27 dogs met the inclusion criteria and were enrolled: 18 (66.6%) of them received adjuvant AC (group 1), whereas the remaining 9 (33.3%) were treated with ADTIC (group 2). Features of the dogs are listed in Table 2 .
At admission, the two treatment groups did not differ for age, body weight, breed, sex, primary location of the tumour and stage, whereas surgical margins were more often incomplete in dogs allocated to receive ADTIC than in those allocated to receive AC [5 of 9 (55.6%) versus 2 of 18 (11.1%), respectively; P = 0.024].
Group 1
There were nine mixed breed dogs, two Boxer, two German shepherd, two Golden retrievers, one English setter, one Labrador retriever and one Italian cane corso. Median age was 9.5 years (range: 6-13 years) and median weight was 31 kg (range: 5.2-46.4 kg). There were 11 males (n = 3 neutered) and 7 female dogs (n = 4 spayed). HSA occurred in the spleen as primary site in 15 dogs: 11 of them presented with hemoabdomen because of splenic rupture. The remaining three dogs had a renal, hepatic and a subcutaneous HSA, respectively.
Each dog underwent surgery, consisting of splenectomy, left hepatic lobectomy, nephrectomy or removal of the subcutaneous tumour, according to cancer location. Histopathological evaluation revealed clean surgical margins in the hepatic and subcutaneous HSA.
According to the TNM classification, 16 dogs were considered having stage II and 2 having stage III HSA. Both dogs with stage III disease had a splenic HSA and macroscopic evidence of metastasis to the omentum; metastatic disease was suspected during celiotomy, and this was confirmed through histopathological examination. Multiple miliary lesions were observed, and metastasectomy could not be performed. No regional lymphadenomegaly and/or other metastatic sites could be documented. Cases are summarized in Table 2 .
The median time from surgery to the initiation of chemotherapy was 9 days (range: 7-10 days). The median number of chemotherapy cycles was 4 (range: 2-5), with a median cumulative dose of doxorubicin of 120 mg m -2 and a median cumulative dose of cyclophosphamide of 1200 mg m −2 . The median received SDIs for this protocol corresponded to the intended SDIs, as none of the dogs required dose reductions and/or treatment delays.
Group 2
There were six mixed breed dogs, one American Staffordshire terrier, one Golden retriever and one Labrador retriever. Median age was 9 years (range: 8-14 years) and median weight was 26.4 kg (range: 10-39.2 kg). There were three males (n = 1 neutered) and six female dogs (n = 4 spayed). HSA occurred in the spleen as primary site in five dogs; all of them presented with hemoperitoneum because of splenic rupture. Two dogs had subcutaneous HSA, one dog had a renal and one had a mesenteric HSA. According to the TNM classification, six dogs had stage II HSA (n = 2 splenic, n = 2 subcutaneous, n = 1 renal and n = 1 mesenteric), and three dogs had stage III HSA (n = 3 splenic). One dog with subcutaneous stage II HSA had lymphadenomegaly of the ipsilateral regional lymph node; this was surgically excised, and metastatic disease was confirmed on histopathology. Two of the three dogs with stage III disease had peritoneal metastases, and one had liver metastases. All dogs Table 2 .
The median time from surgery to the initiation of chemotherapy was 9 days (range: 7-10 days). The median number of chemotherapy cycles was 4 (range: 2-4 cycles), with a median cumulative dose of doxorubicin of 120 mg m −2 (range: 60-120 mg m −2 ) and a median cumulative dose of dacarbazine of 4000 mg m −2 (range: 2000-4000 mg m −2 ). The median number of chemotherapy cycles was 4 (range: 2-4). The median received SDIs for this protocol corresponded to the intended SDIs.
Additional treatments
Additional treatments were permitted at the time of development of metastatic disease. These were instituted only in three dogs. In group 1, a dog with splenic stage II HSA received cyclophosphamide and piroxicam in a metronomic regimen, and in group 2, a dog with stage II renal HSA and one with splenic stage III HSA received ifosfamide followed by masitinib mesylate.
Clinical outcomes
Thirteen (72.2%) of the eighteen dogs in group 1 developed metastatic disease after a median of 89 days (range: 44-188 days). Metastases were found in the liver (n = 7), lungs (n = 3), peritoneum (n = 2), liver and lungs (n = 1). The two dogs with metastases to the peritoneum developed haemoabdomen. One (11.1%) of the nine dogs included in group 2 developed pulmonary metastasis after 378 days. Of the three dogs already having metastasis at presentation, two had disease progression documented after 48 and 70 days, respectively. In these dogs, metastases were found in the lungs (n = 1), kidney and liver (n = 1), respectively. Overall, median TTM as calculated with Kaplan-Meier product limit was significantly longer for dogs receiving ADTIC compared with those receiving AC (>550 days versus 112 days, respectively; P = 0.021; Fig. 1) .
Sixteen (88.8%) of the eighteen dogs included in group 1 died by the end of the study: 15 (83.3%) died as a result of HSA progression with a median survival time of 140 days (range: 37-301 days), whereas one dog died after 158 days because of gastric dilatation-volvulus with no evidence of tumour recurrence or metastasis. Two dogs with splenic stage II HSA were still alive, 85 and 262 days after the diagnosis, respectively. Seven (77.7%) of the nine dogs in group 2 died by the end of the study: four (44.4%) died as a result of HSA progression with a median survival time of 106 days (range: 74-480 days). Of these four dogs, three had splenic stage III HSA and one had renal stage II HSA. Regarding the remaining three, one of them (splenic stage II HSA) died 803 days after the diagnosis owing to gastric dilatation-volvulus, one (splenic stage II HSA) died after 960 days owing to advanced chronic kidney disease [international renal interest society (IRIS) stage IV] and one (mesenteric stage II HSA) died after 1230 days owing to a metastatic mast cell tumour. Two dogs with subcutaneous stage II HSA were still alive, 572 and 1260 days after the diagnosis. Overall, dogs receiving ADTIC had significantly longer median survival than those receiving AC (>550 days versus 142 days, respectively; P = 0.011; Fig. 2 ). In group 1 none of the dogs was alive at 1 year after diagnosis, whereas in group 2 the 1-and 1.5-year survival rates were 66.8 and 55.8%, respectively.
Safety
All dogs were evaluated for toxicity. In group 1, a total of 77 CBCs were evaluated; neutropenia was the only type of bone marrow toxicity, occurring in six (33.3%) dogs. Grade 1 neutropenia occurred in five dogs, whereas one dog developed a grade-3 non-febrile neutropenia. In all dogs, neutropenia developed after the first treatment and resolved without sequel. No further hematological toxicities were recorded. In group 2, a total of 96 CBCs were evaluated; neutropenia was the only type of bone marrow toxicity, occurring in 7 (77.7%) dogs, 10 days after day 1 of chemotherapy. Two episodes of grade 1 neutropenia occurred in one dog, six episodes of grade 2 neutropenia occurred in five dogs, four episodes of grade 3 neutropenia occurred in two dogs and one episode of grade 4 non-febrile neutropenia occurred in one dog. Two dogs developed neutropenia after each cycle, two dogs after the third cycle and two dogs had only one episode of neutropenia during treatment. Among them, one developed a grade 2 febrile neutropenia after the second cycle, which resolved uneventfully after symptomatic treatment. The median number of cycles administered before developing neutropenia was 2 (range: 1-2 cycles), and the median number of cycles with dogs showing neutropenia was 3 (range: 1-4 cycles). In all dogs, neutropenia resolved without sequel.
The frequency of neutropenia was higher in dogs that received ADTIC than in those that received AC (7 of 9 (77.8%) versus 6 of 18 (33.3%), respectively; P = 0.046).
Gastrointestinal toxicity was the second most common adverse event in both groups, which consisted of vomiting and decreased appetite. Gastrointestinal toxicity occurred in seven (38.8%) dogs in group 1: two dogs had grade 1 side effects (one concurrently had grade 1 neutropenia), four dogs had grade 2 (2 concurrently had grade 1 neutropenia) and one dog had grade 3 toxicity. In every case, a single episode of gastrointestinal toxicity was recorded. In group 2, three (33.3%) dogs developed gastrointestinal toxicity; two dogs had grade 1 (one concurrently had grade 1 neutropenia) and one had grade 2 toxicity. The frequency of gastrointestinal side effects did not differ between groups (P = 1.000). Alopecia occurred in one dog in group 1 at the end of the fourth cycle. No other toxicities were recorded.
Discussion
The treatment of HSA continues to be extremely challenging in veterinary oncology, and prognosis for dogs with HSA is poor as a result of aggressive disease, leading to invasion of nearby organs and vessels, early metastasis and limited treatment options providing durable disease control. Surgery is designed to remove all macroscopic tumours and prevent further risk of acute haemorrhage, but is considered purely palliative. The addition of chemotherapy in an effort to treat microscopic disease has been documented to provide a modest improvement in outcome, with reported median survival times in the range of 6-8 months and less than 10% of dogs being alive at 12 months. 1, 2 In this study, we used a combination of doxorubicin and dacarbazine as adjuvant chemotherapy to determine the safety and efficacy of this treatment in biologically aggressive canine HSA.
This study showed that the ADTIC combination is feasible and can be safely administered every 21 days in dogs with HSA, thereby allowing compliance with projected drug doses and scheduled intervals between cycles. All dogs were treated on an outpatient basis, stressing the feasibility of the presently described ADTIC regimen. Side effects were reversible and manageable, with neutropenia being the primary toxicity. One dog experienced febrile grade 2 neutropenia after the second cycle and one asymptomatic grade 4 neutropenia after the third cycle; however, they both recovered with supportive care, and subsequent dose reductions were not considered necessary. Notably, none of the dogs developed sepsis due to neutropenia.
Although the prophylactic use of antibiotics in dogs receiving combination chemotherapy is still controversial, it is possible that the administration of clavulanate-potentiated amoxicillin was effective in reducing the neutropenic episodes and the related adverse effects.
Overall, the incidence of gastrointestinal toxicity (vomiting and loss of appetite) was low, and no significant differences were observed between groups 1 and 2. We assume that the standard antiemetic medication with maropitant prevented the onset of grades 3-4 emesis. It is possible that a longer maropitant administration (over 5 consecutive days) might have reduced the occurrence of vomiting further.
Specific guidelines for dose adjustments of antineoplastic agents are not standardized in veterinary oncology; however, a 20-25% reduction is commonly recommended for the subsequent dose in patients experiencing moderate-severe dose-limiting toxicity (i.e. grade 3-4 toxicities), such as neutropenia or emesis. 32 Excessive toxicity is also more likely to increase treatment-associated costs, has chances of losing owners' compliance and, least but not last, to negatively affect patients' survival. On the other hand, the greatest benefit achievable with anticancer cytotoxic therapy requires a commitment to dose intensity; lack of or reduced dose density has the potential to be detrimental in cancer treatment, especially in neoplastic diseases known to have the potential of high growth fractions. 33, 34 Of course, optimal dose intensity demands therapeutic monitoring in order to either reduce or increase doses based on the patient's capacity to maintain a high quality of life (QoL) during effective therapy. In the mentioned cases, a close monitoring of clinical signs by the clinicians and detailed owners' information resulted in no lack of compliance. Dogs recovered completely and haematological abnormalities resolved without requiring hospitalization and with no perception of durable decline in QoL by the owner. We therefore elected not to reduce chemotherapy doses at the time of the following cycle, resulting in no effect on the intended SDIs of the chemotherapy protocol. Such toxicities did not recur during treatment, being attributable to transient and undiagnosed comorbidities that might have enhanced chemotherapy toxicities, a degree of individual tolerance to chemotherapy, adaption of the owner to gastrointestinal signs or a combination of these. Our approach was based on the thought that dose reductions should not be solely based on the degree of toxicity, but decided on a broader spectrum of variants such as risk of cancer progression, presenting clinical signs and owner compliance. Moreover, cumulative toxicity was also not observed in our study; in fact, haematological abnormalities were reversible and the degree of toxicity (either hematological of gastrointestinal) did not increase in the following treatment cycles.
These results differ from a recent publication that reported the use of combined chemotherapy protocol consisting of DAV. 15 In that study, chemotherapy-related side effects were notable, including several high-grade hematologic and gastrointestinal toxic events. Moreover, almost 20% of the dogs had their protocol discontinued as a result of chemotherapy-related toxicities; however, no treatment-related deaths occurred. 15 This could have multiple explanations. In this study, the total intended dose of dacarbazine was divided into five daily boluses, whereas in the DAV study this was administered as a single dose over 8-h infusion; in fact, it has been suggested that daily dacarbazine IV boluses may cause reduced gastrointestinal toxicity than slow IV infusions, without negatively affecting antitumour activity. 16, 28 Moreover, vincristine was not administered in ADTIC dogs, possibly reducing the risk of gastrointestinal toxicity. It should also be noted that the majority of dogs included in group 2 presented with no advanced clinical stage, whereas in the DAV study dogs were most likely to have stage III disease; dogs with advanced disease could easily have reduced performance status, potentially leading to enhanced susceptibility to chemotherapy toxicity. 35 No evidence of clinical cardiotoxicity was noted in our study. This finding could be attributed to the entry criteria with regard to cardiac function, the limited number of dogs in the study and/or the low number of doxorubicin treatments administered not reaching the cumulative dose for cardiotoxicity.
Despite the small size of this study, our results document an advantage in the use of ADTIC over AC for the treatment of biologically aggressive canine HSA in terms of metastatic control and survival, particularly for stage II HSA. In group 1, 83% of dogs (AC protocol) were euthanized because of HSA progression with an MST of 142 days, whereas in group 2 (ADTIC protocol) 44.4% of dogs died because of tumour-related causes with an MST >550 days (P = 0.011); moreover, in group 2, the one and one-and-a half-year survival was achieved in 66.8 and 55.8%, respectively, whereas none of the patient reached one-year survival in group 1. From our perspective, these data are probably the most relevant supporting the benefit of ADTIC on patients' survival further, and may also suggest that a notable proportion of dogs with biologically aggressive HSA may still have a good outcome, if chemotherapy is started in the absence of macroscopic metastatic disease. However, these data should be interpreted carefully as it may be biased by the small number of dogs enrolled in group 2 and, although debated, to the potentially less aggressive biological behaviour of renal and subcutaneous HSA compared with other visceral locations. 4, 36 This being said, it must be acknowledged that subcutaneous HSA with the longest diameter >6 cm has significantly been associated with a shorter time to tumour progression and survival time than smaller tumours. 4 In this study, the three subcutaneous HSA measured 8, 6.5 and 12 cm, respectively, supporting the aggressive behaviour and the increased likelihood of developing metastatic disease. Also, one of these dogs had metastatic disease in the regional lymph node, further supporting the aggressive biological behaviour.
Concerning TTM, 66.6% of the dogs treated with AC developed distant metastasis during the study compared with 44% of the dogs treated with ADTIC. Like survival, TTM was significantly longer (P = 0.021) if ADTIC was used as adjuvant first-line treatment strategy. This finding may be due to several reasons. Although both cyclophosphamide and dacarbazine are alkylating agents, their antitumour activity differs considerably because of different pharmacokinetic features, lipid solubility, membrane transport properties and specific enzymatic reactions capable of repairing alkylation sites on DNA. 16, 37 Cyclophosphamide interferes with DNA replication and transcription of RNA, thereby resulting in the disruption of nucleic acid function. 37 Dacarbazine acts by means of alkylation, antimetabolite activity as a purine precursor, and interaction with sulfhydryl groups in proteins. 16 Because the issue of optimizing the treatment strategy to maximize efficacy while limiting toxicity has clinical implications, here we further investigated dose intensity of both adopted protocols by directly comparing cyclophosphamide and dacarbazine. Dacarbazine has greater individual fractional dose intensity when compared with cyclophosphamide, ultimately leading to a greater SDI in combination with doxorubicin. All dogs included in the study received the scheduled doses without any need for dose reduction; therefore, ADTIC-treated dogs received a more intense chemotherapy, possibly leading to longer TTM and survival. Furthermore, besides its cytotoxic activity, dacarbazine has been demonstrated to have antimetastatic property in mice, the underlying mechanism being related to its capacity to enhance tumour immunogenicity. 38, 39 In this study, dogs treated with ADTIC had a longer TTM, which may either reflect the capacity of dacarbazine to inhibit metastatic spread or be because of the small sample size of the study.
Limitations of this study include lack of randomization, low number of cases, different tumour site origin and lack of necropsy. Although subcutaneous and visceral HSA have been described to have an aggressive biological behaviour, 1, 3, 4 little is known about mesenteric HSA. 2 A dog with mesenteric HSA was included in this study. In addition, two dogs included in group 2 received a rescue protocol after having developed distant metastases, possibly contributing to increased survival. Also, the two treatment options (AC versus ADTIC) were offered at different clinics, instead of offering either treatment at each location, possibly leading to selection bias. However, the analysis of the groups confirmed that these did not have significant differences, except for the number of patients enrolled, suggesting that the samples were homogeneous.
To conclude, the combination ADTIC was well tolerated and may prolong TTM and survival time in dogs with biologically aggressive HSA, especially if not metastatic at presentation.
